Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences is working to eradicate cancer by delivering a portfolio that gives providers the information they need to better serve their patients across the cancer care continuum — starting with familial risk.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
Exact Sciences expects the test to be available in 2025, pending approval.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
The company’s commitment to community involvement keeps paying off when employees get back from giving back.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
The Riskguard™ test is an assessment tool that can help uncover hereditary cancer risk. With just a simple blood or saliva sample, it checks for hereditary genetic changes that can cause an increased risk for certain cancers.
See the difference the Riskguardtest can make for your patients.
See the difference the Riskguardtest can make for you.
Have peace of mind knowing patients and providers can form better treatment and prevention journeys guided by genetics.1-6
Receive easy-to-understand results with potential next steps that providers and patients can use for personalized care planning.
We understand navigating coverage can be overwhelming. Exact Sciences* is an in-network provider with many health plans. We offer insurance billing and flexible payment options.
Coverage for eligible patients including Medicare and commercial insurance
Specialized support for billing insurance and prior authorization
Flexible payment options for patients
Learn More
With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at 1-866-662-6897 or email us at riskguard@exactsciences.com.
* The terms of this product offering are subject to change and not offered permanently or in perpetuity. Any modifications are to be considered effective once published on this website.
References
1 Geyer CE Jr, Garber JE, Gelber RD, et al; OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-1268.
2 Hussain M, Mateo J, Fizazi K, et al; PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345-2357.
3 Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
4 Ledermann J, Harter P, Gourley C, et al : Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
5 Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
6 Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. Genomic Health, Inc., an Exact Sciences company, is the billing entity for Riskguard.